Repare Therapeutics (RPTX) News Today $3.11 -0.14 (-4.31%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibNovember 13, 2024 | finance.yahoo.comMorgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)November 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue ForecastsNovember 13, 2024 | finance.yahoo.comRepare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy RatingNovember 11, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRepare Therapeutics: Strategic Clinical Advancements and Promising Data Drive ‘Buy’ RatingNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Reports Q3 2024 Progress and OutlookNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comRepare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical OutcomesOctober 25, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)October 25, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Repare Therapeutics (NASDAQ:RPTX)HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.comRepare Therapeutics Inc.: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialOctober 24, 2024 | finanznachrichten.deRepare Therapeutics presents data from Phase 1 MYTHIC clinical trialOctober 24, 2024 | markets.businessinsider.comRepare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialOctober 23, 2024 | businesswire.comRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase InhibitorOctober 14, 2024 | businesswire.comRepare Therapeutics maintains stock target, positive trial outlookOctober 3, 2024 | uk.investing.comHold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety ConcernsOctober 2, 2024 | markets.businessinsider.comRepare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual MeetingSeptember 30, 2024 | businesswire.comRepare Therapeutics Inc. (NASDAQ:RPTX) Shares Bought by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP raised its position in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 8.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,372,499 shares of the companSeptember 28, 2024 | marketbeat.comRepare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the companySeptember 27, 2024 | finance.yahoo.comBuy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Data and Market PotentialSeptember 24, 2024 | markets.businessinsider.comBSF Enterprise Plc (BSFA.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comRepare Therapeutics (NASDAQ:RPTX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Monday.September 23, 2024 | marketbeat.comRepare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic CancersSeptember 23, 2024 | businesswire.comPiper Sandler Sticks to Its Buy Rating for Repare Therapeutics (RPTX)September 16, 2024 | markets.businessinsider.comAcadian Asset Management LLC Purchases 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)Acadian Asset Management LLC increased its stake in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 212.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 417,929 shares of the company's stock after buying an additional 284,036 shares during the qSeptember 16, 2024 | marketbeat.comRepare Therapeutics Inc. (NASDAQ:RPTX) Forecasted to Post FY2025 Earnings of ($2.79) Per ShareRepare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Investment analysts at Bloom Burton issued their FY2025 earnings per share (EPS) estimates for shares of Repare Therapeutics in a research note issued to investors on Thursday, September 12th. Bloom Burton analyst D. Martin expects that the cSeptember 13, 2024 | marketbeat.comBuy Recommendation: Repare Therapeutics’ Strong Science and Financial Runway Despite SetbackSeptember 13, 2024 | markets.businessinsider.comHold Rating on Repare Therapeutics Awaits Key Clinical Data and Market Potential RealizationSeptember 9, 2024 | markets.businessinsider.comQ3 2024 EPS Estimates for Repare Therapeutics Inc. Decreased by Analyst (NASDAQ:RPTX)Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings estimates for Repare Therapeutics in a research note issued to investors on Wednesday, September 4th. HC Wainwright analyst R. Burns now forecasts that the company will earSeptember 6, 2024 | marketbeat.comBuy Rating on Repare Therapeutics: Strategic Reprioritization and Upcoming Catalysts Bolster Long-Term ProspectsSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Repare Therapeutics (NASDAQ:RPTX)HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Wednesday.September 4, 2024 | marketbeat.comBuy Rating on Repare Therapeutics Amidst Promising Clinical Trials and Strong FinancialsSeptember 3, 2024 | markets.businessinsider.comMontreal-Cambridge biotech to lay off 25% of teamAugust 31, 2024 | bizjournals.comRepare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib DataAugust 31, 2024 | seekingalpha.comRepare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic LandscapeAugust 29, 2024 | msn.comRepare Therapeutics: A Promising Penny Stock in Canada’s Evolving Economic LandscapeAugust 29, 2024 | finance.yahoo.comRepare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic LandscapeAugust 29, 2024 | msn.comStrategic Restructuring and Promising Pipeline Underpin Buy Rating for Repare TherapeuticsAugust 29, 2024 | markets.businessinsider.comRepare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioAugust 28, 2024 | businesswire.comBuy Rating Affirmed for Repare Therapeutics Amid Promising Clinical Data and Strategic Financial PositioningAugust 20, 2024 | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for Repare Therapeutics (RPTX)August 20, 2024 | markets.businessinsider.comRPTX Sep 2024 5.000 put (RPTX240920P00005000)August 17, 2024 | finance.yahoo.comFY2028 Earnings Estimate for Repare Therapeutics Inc. Issued By Capital One Financial (NASDAQ:RPTX)Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Equities research analysts at Capital One Financial raised their FY2028 earnings per share (EPS) estimates for Repare Therapeutics in a research note issued to investors on Thursday, August 8th. Capital One Financial analyst T. Chiang now expAugust 12, 2024 | marketbeat.comRepare Therapeutics: Strong Q2 Financials and Upcoming Catalysts Bolster Buy RatingAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Repare Therapeutics Amid Anticipated Catalysts and Strong FinancialsAugust 9, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Announces Earnings Results, Beats Expectations By $0.03 EPSRepare Therapeutics (NASDAQ:RPTX - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.03. Repare Therapeutics had a negative return on equity of 19.81% and a negative net margin of 46.69%. The firm had revenue of $1.07 million during the quarter, compared to analysts' expectations of $4.02 million.August 7, 2024 | marketbeat.comOptimistic Buy Rating for Repare Therapeutics on Strong Financials and Clinical SuccessAugust 7, 2024 | markets.businessinsider.comRepare Therapeutics Inc.August 1, 2024 | barrons.comWe Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth CarefullyAugust 1, 2024 | finance.yahoo.com Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover RPTX Media Mentions By Week RPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼0.520.55▲Average Medical News Sentiment RPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼52▲RPTX Articles Average Week Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Black Diamond Therapeutics News Mereo BioPharma Group News Corvus Pharmaceuticals News Acelyrin News AnaptysBio News ProKidney News Larimar Therapeutics News Monte Rosa Therapeutics News Alumis News Alector News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
